Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer (Nature Genetics, (2013), 45, 7, (747-755), 10.1038/ng.2650);A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer

Nature Genetics

Volumn 45, Issue 7, 2013, Pages 747-755

  Lunardi, Andrea ^a   Ala, Ugo ^a,b   Epping, Mirjam T ^a   Salmena, Leonardo ^a,c   Clohessy, John G ^a,c   Webster, Kaitlyn A ^a   Wang, Guocan ^a,c,d   Mazzucchelli, Roberta ^e   Bianconi, Maristella ^e   Stack, Edward C ^a,f   Lis, Rosina ^a,f   Patnaik, Akash ^a   Cantley, Lewis C ^a,g   Bubley, Glenn ^a   Cordon Cardo, Carlos ^h   Gerald, William L ^c   Montironi, Rodolfo ^e   Signoretti, Sabina ^a   Loda, Massimo ^a,f,i   Nardella, Caterina ^a,c   Pandolfi, Pier Paolo ^a,c   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d Weill Cornell Graduate School of Biomedical Sciences   (United States)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BICALUTAMIDE; CHARCOAL; DEXTRAN; DUTASTERIDE; EMBELIN; ENZALUTAMIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN TRP53; PROTEIN XAF1; PROTEIN ZBTB7A; STEROID 5ALPHA REDUCTASE 1; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANDROGEN DEPRIVATION THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GENETICS; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH;

EID: 84879671701     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/s41588-020-0701-7     Document Type: Erratum

References (49)

1. Nardella, C., Lunardi, A., Patnaik, A., Cantley, L.C. & Pandolfi, P.P. The APL paradigm and the "co-clinical trial" project. Cancer Discov. 1, 108-116 (2011).
2. Catalona, W.J. Management of cancer of the prostate. N. Engl. J. Med. 331, 996-1004 (1994).
3. Molina, A. & Belldegrun, A. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J. Urol. 185, 787-794 (2011).
4. Wang, G. et al. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat. Genet. published online; doi:10.1038/ng.2654 (2 June 2013).
5. Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730 (2005).
6. Schlomm, T. et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod. Pathol. 21, 1371-1378 (2008).
7. Tepper, C.G. et al. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells. Prostate 65, 375-389 (2005).
8. Markert, E.K., Mizuno, H., Vazquez, A. & Levine, A.J. Molecular classification of prostate cancer using curated expression signatures. Proc. Natl. Acad. Sci. USA 108, 21276-21281 (2011).
9. Abou-Kheir, W.G., Hynes, P.G., Martin, P.L., Pierce, R. & Kelly, K. Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model. Stem Cells 28, 2129-2140 (2010).
10. Kumar, A. et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc. Natl. Acad. Sci. USA 108, 17087-17092 (2011).
11. Taylor, B.S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010).
12. Pourmand, G. et al. Role of PTEN gene in progression of prostate cancer. Urol. J. 4, 95-100 (2007).
13. Trotman, L.C. et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, E59 (2003).
14. Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209-221 (2003).
15. Carver, B.S. et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575-586 (2011).
16. Zhang, W. et al. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res. 69, 7466-7472 (2009).
17. Kent, E.C. & Hussain, M.H. The patient with hormone-refractory prostate cancer: determining who, when, and how to treat. Urology 62 (suppl. 1), 134-140 (2003).
18. Kent, E.C. & Hussain, M.H. Neoadjuvant Therapy for prostate cancer: an oncologist's perspective. Rev. Urol. 5 (suppl. 3), S28-S37 (2003).
19. Liu, W. et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat. Med. 15, 559-565 (2009).
20. Grasso, C.S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012).
21. Lee, S.U. & Maeda, T. POK/ZBTB proteins: an emerging family of proteins that regulate lymphoid development and function. Immunol. Rev. 247, 107-119 (2012).
22. Tomlins, S.A. et al. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39, 41-51 (2007).
23. Baretton, G.B., Klenk, U., Diebold, J., Schmeller, N. & Lohrs, U. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br. J. Cancer 80, 546-555 (1999).
24. Gelmann, E.P. Molecular biology of the androgen receptor. J. Clin. Oncol. 20, 3001-3015 (2002).
25. Liston, P. et al. Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat. Cell Biol. 3, 128-133 (2001).
26. Huang, J. et al. XAF1 as a prognostic biomarker and therapeutic target in pancreatic cancer. Cancer Sci. 101, 559-567 (2010).
27. Tu, S.P. et al. Restoration of XAF1 expression induces apoptosis and inhibits tumor growth in gastric cancer. Int. J. Cancer 125, 688-697 (2009).
28. Jiang, C., Yi, X.P., Shen, H. & Li, Y.X. Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion. World J. Gastroenterol. 18, 2956-2965 (2012).
29. Dai, Y. et al. Adenovirus-mediated down-regulation of X-linked inhibitor of apoptosis protein inhibits colon cancer. Mol. Cancer Ther. 8, 2762-2770 (2009).
30. Qiao, L. et al. Gene expression profile in colon cancer cells with respect to XIAP expression status. Int. J. Colorectal Dis. 24, 245-260 (2009).
31. Dubrez-Daloz, L., Dupoux, A. & Cartier, J. IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle 7, 1036-1046 (2008).
32. Nikolovska-Coleska, Z. et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J. Med. Chem. 47, 2430-2440 (2004).
33. Zou, B. et al. XIAP-associated factor 1 (XAF1), a novel target of p53, enhances p53-mediated apoptosis via post-translational modification. Mol. Carcinog. 51, 422-432 (2012).
34. Chang, K.H. et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc. Natl. Acad. Sci. USA 108, 13728-13733 (2011).
35. Yamaoka, M., Hara, T. & Kusaka, M. Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. Clin. Cancer Res. 16, 4319-4324 (2010).
36. Luo, J.H. et al. Gene expression analysis of prostate cancers. Mol. Carcinog. 33, 25-35 (2002).
37. Liu, P. et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res. 66, 4011-4019 (2006).
38. LaTulippe, E. et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 62, 4499-4506 (2002).
39. Stephenson, A.J. et al. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 104, 290-298 (2005).
40. Dai, Y. et al. Natural IAP inhibitor Embelin enhances therapeutic efficacy of ionizing radiation in prostate cancer. Am. J. Cancer Res. 1, 128-143 (2011).
41. Taplin, M.E. et al. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin. Cancer Res. 15, 7099-7105 (2009).
42. Sartor, O., Gomella, L.G., Gagnier, P., Melich, K. & Dann, R. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. Can. J. Urol. 16, 4806-4812 (2009).
43. Sartor, O. et al. Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. Clin. Genitourin. Cancer 7, E90-E92 (2009).
44. Varambally, S. et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8, 393-406 (2005).
45. Danquah, M., Duke, C.B. III, Patil, R., Miller, D.D. & Mahato, R.I. Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer. Pharm. Res. 29, 2079-2091 (2012).
46. Chen, Z. et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 483, 613-617 (2012).
47. Maeda, T. et al. LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis. Dev. Cell 17, 527-540 (2009).
48. Wu, X. et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech. Dev. 101, 61-69 (2001).
49. Nastiuk, K.L. et al. In vivo MRI volumetric measurement of prostate regression and growth in mice. BMC Urol. 7, 12 (2007).